NASDAQ:DARE Dare Bioscience Q2 2026 Earnings Report $1.93 -0.14 (-6.76%) As of 03:09 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Dare Bioscience EPS ResultsActual EPSN/AConsensus EPS -$0.33Beat/MissN/AOne Year Ago EPSN/ADare Bioscience Revenue ResultsActual RevenueN/AExpected Revenue$0.00 millionBeat/MissN/AYoY Revenue GrowthN/ADare Bioscience Announcement DetailsQuarterQ2 2026Date8/13/2026TimeAfter Market ClosesConference Call DateThursday, August 13, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Dare Bioscience Earnings HeadlinesDare Bioscience Enters Commercial Stage With Women’s Health Launches, Pipeline UpdatesJuly 16 at 5:04 AM | americanbankingnews.comDaré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell EventJuly 9, 2026 | globenewswire.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.July 16 at 1:00 AM | Banyan Hill Publishing (Ad)Daré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer PlatformJuly 1, 2026 | globenewswire.comDaré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” SegmentJune 25, 2026 | globenewswire.comDaré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026June 18, 2026 | globenewswire.comSee More Dare Bioscience Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Dare Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dare Bioscience and other key companies, straight to your email. Email Address About Dare BioscienceDare Bioscience (NASDAQ:DARE) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use. In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery. The company’s research strategy emphasizes platform versatility, enabling potential applications in areas such as mucosal immunization and topical therapies for vaginal health. Dare collaborates with academic institutions and strategic partners to leverage emerging technologies and expand its product opportunities within the women’s health market. Headquartered in San Diego, California, Dare Bioscience operates in the United States and is listed on the Nasdaq Global Market under the ticker symbol DARE. The company is led by a management team with extensive experience in pharmaceutical development, regulatory affairs and commercial execution. Dare’s leadership is committed to advancing its clinical programs and delivering new options for women’s reproductive care.View Dare Bioscience ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Revving Up Returns: Big Banks Race Through the Rate PlateauWhy Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the TestAI’s Power Crunch Fuels a Pivot for These 2 Oilfield StocksToast’s Comeback Story Is Getting Harder for Wall Street to IgnoreWhy Conagra’s Dividend Cut Could Be the Best Thing for InvestorsWhich Storage Stock Is Best Positioned to Win the AI Memory War?Cintas Keeps Beating Expectations—And the Story Isn’t Over Upcoming Earnings Fifth Third Bancorp (7/17/2026)Truist Financial (7/17/2026)Travelers Companies (7/17/2026)HDFC Bank (7/18/2026)ICICI Bank (7/18/2026)General Motors (7/21/2026)Northrop Grumman (7/21/2026)America Movil (7/21/2026)Alphabet (7/21/2026)Chubb (7/21/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
